Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

RBD Dimer recombinant protein vaccine against SARSCoV2

Project description

Innovative platform for the recombinant vaccines against COVID-19 variants

The EU-funded RBDCOV project aims to test two new vaccines against the Wuhan and South African/United Kingdom variants of SARS-CoV-2 using data on the application of recombinant protein developed by the project partners. The project will include a Phase I/II clinical trial of the Wuhan vaccine for the paediatric population and Phase I/II of adjuvant recombinant receptor-binding domain (RBD) protein of South African/United Kingdom variants for booster vaccination in adults. Monitoring of the new emerging variants will be performed to ensure platform readiness. The platform for the vaccines is adaptable and will be ready to include in the design the future new variants. The RBDCOV consortium will have the opportunity to generate the first RBD recombinant vaccine to be approved in Europe.

Objective

The main objective of RBDCOV project is to test the efficacy, tolerability, and safety of a new vaccine against different variants of COVID-19 based on the outstanding data generated using a recombinant protein developed by the consortium partners. Two different clinical trials will be run during the project duration to test the variants recombinant RBD protein vaccine, codifying for Beta and Alpha SARS-Cov-2 variants in paediatric population and in immunocompromised adults.

The aim of the project is to focus not only on the current SARS-CoV-2 variants but also in the emerging ones as Beta and Alpha variants. Thus, a continuous monitoring of the new emerging variants will be performed throughout the project to ensure that the platform is prepared to cope with the disease. The platform used for the generation of the vaccines is adaptable to variants and will be ready to include in the design any other potential variant that could appear in short, medium and large term. Preclinical data are already available.

The core of RBDCOV consortium has been in close contact to the corresponding agencies and considering Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2, preclinical data supporting the first vaccine candidate can be extrapolated for the vaccines against the new emerging variants. This create a unique opportunity for RBDCOV consortium to generate the first RBD recombinant vaccine to be approved in Europe. This vaccine will be manufactured by an European technological company that will change actual paradigms and allow the really change to One health concept, based on the close relationship between the animal world and the onset of certain infections in humans.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2021-CORONA-01

See all projects funded under this call

Coordinator

HIPRA SCIENTIFIC SL
Net EU contribution
€ 1 096 898,79
Address
AVINGUDA LA SELVA 135
17170 Amer
Spain
Region
Este Cataluña Girona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 895 348,58

Participants (19)